PLx Pharma Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma or view top-rated stocks.

Wall Street analysts have given PLx Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PLx Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

PLx Pharma saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,480,000 shares, an increase of 24.4% from the June 30th total of 1,190,000 shares. Based on an average daily volume of 469,200 shares, the days-to-cover ratio is currently 3.2 days. Approximately 7.9% of the shares of the company are short sold.
View PLx Pharma's Short Interest.

PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for PLx Pharma.

PLx Pharma will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "8277376".

PLx Pharma Inc. (NASDAQ:PLXP) released its quarterly earnings results on Friday, May, 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.56.
View PLx Pharma's earnings history.

PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PLXP shares have increased by 282.7% and is now trading at $18.41.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1 year price objectives for PLx Pharma's shares. Their forecasts range from $21.00 to $22.00. On average, they expect PLx Pharma's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts' price targets for PLx Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to PLx Pharma include Global Blood Therapeutics (GBT), Constellation Pharmaceuticals (CNST), Avid Bioservices (CDMO), ADC Therapeutics (ADCT), NGM Biopharmaceuticals (NGM), Harmony Biosciences (HRMY), Innoviva (INVA), PMV Pharmaceuticals (PMVP), Arcturus Therapeutics (ARCT), Prelude Therapeutics (PRLD), Day One Biopharmaceuticals (DAWN), MacroGenics (MGNX), Nurix Therapeutics (NRIX), Y-mAbs Therapeutics (YMAB) and Amneal Pharmaceuticals (AMRX).
View all of PLXP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

PLx Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Eidelman Virant Capital (0.08%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino and Rita M O'connor.
View institutional ownership trends for PLx Pharma.

PLXP stock was bought by a variety of institutional investors in the last quarter, including Eidelman Virant Capital. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma or or view top insider-buying stocks.

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLXP stock can currently be purchased for approximately $18.41.

PLx Pharma has a market capitalization of $420.48 million and generates $30,000.00 in revenue each year. The biotechnology company earns $-15,210,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

PLx Pharma employs 8 workers across the globe.

The official website for PLx Pharma is www.plxpharma.com.

PLx Pharma is headquartered at 9 Fishers Lane Suite E, Sparta NJ, 07871.

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 973-409-6541 or via email at [email protected]